Stryker reported revenue growth of approximately 8% year-over-year in its most recent quarter, outpacing the med-tech sector average of 5%. Despite this outperformance, the company’s share performance has remained flat over the past six months, reflecting broader sector derating and heightened investor caution around high-multiple healthcare names. Management reiterated its full-year guidance of mid-single-digit top-line growth and operating margin expansion of 100 basis points, but analysts note that multiple contraction has offset much of the gains from stronger fundamentals.

The Mako robotic system remains Stryker’s fastest-growing division, with major joint segment sales up 15% in calendar 2025. The company has increased its installed base of Mako units by over 200 systems globally during the last year, driving procedure volume growth of 20%. Management is now leveraging its robotics platform into upper and lower extremities, expecting that these additional procedure types could contribute up to $200 million in incremental revenue by 2027. Adoption in ambulatory surgical centers has grown by 25%, reflecting the system’s ease of use and cost efficiencies in outpatient settings.

Stryker’s capital allocation priorities emphasize acquisitions in robotics, cardiology and urology to broaden its technology portfolio. In 2025, the company completed two tuck-in deals totaling $450 million, adding complementary imaging and navigation solutions. Management has earmarked $2 billion for potential bolt-on transactions over the next 12 months, targeting assets that can be integrated into its Smart Care digital platform. Share repurchases remain part of the capital return program, with $1.2 billion executed through Q3, representing roughly 55% of free cash flow.

Beyond M&A, Stryker sees organic growth opportunities in its Smart Care ecosystem—an integrated suite of connected operating room solutions. The division grew 22% in 2025, driven by subscription-based software and service contracts with health systems. Operating margins expanded to 27.5%, up from 26.3% a year earlier, as the company achieved scale efficiencies in manufacturing and logistics. Analysts forecast that continued margin leverage and recurring revenue from Smart Care could add 150 basis points to operating income over the next two years.